Day 6

The Silent Saboteur: how leaky Cre shapes (and skews) in vivo immunology

One of the major technical bottlenecks in doing rigorous in vivo immunology with mouse Cre/lox systems is “leaky Cre” activity defined as the recombination that occurs in the wrong cells, at the wrong time, or even in the absence of intentional induction, silently scrambling the very compartments we think we are manipulating. Since Orkin’s 1999 paper in PNAS, we’ve known of Cre activity in unexpected lineages or developmental windows (PNAS). Over the years increasingly sensitive indicators have revealed ectopic, germline, and tamoxifen-independent recombination across many ostensibly tissue- or time-restricted Cre and CreERT2 lines (Blank, Palmer and Tallquist). Against that backdrop, this new work on leaky or under-reporting Cre in T cells (by Kansas) should be read as part of a larger cautionary story: in myeloid and macrophage biology as much as in lymphocytes, the fidelity of our conclusions is often limited less by the elegance of our hypotheses than by the quiet, cumulative consequences of imperfect Cre control.

In Kansas’s paper - a widely used Rosa26 EYFP Cre-reporter line (R26^EYFP, JAX 007903) substantially under-reports Cre activity in T cells compared with an otherwise identical tdTomato reporter (R26^tdTomato, JAX 007914) when driven by distal Lck–Cre (dLcK-Cre). In dlck-Cre × R26^EYFP/tdTomato mice, CD4⁺ and CD8⁺ single-positive thymocytes and peripheral naïve T cells segregated into two major Cre⁺ populations: EYFP⁺tdTomato⁺ and tdTomato⁺EYFP⁻, with virtually no EYFP⁺tdTomato⁻ cells. The tdTomato-only population was consistently present in all mice and in both CD4 and CD8 lineages, indicating that a substantial fraction of bona fide Cre-expressing T cells never turn on EYFP, despite identical locus and regulatory elements. EYFP and tdTomato patterns in earlier thymic stages and in B cells and NK cells matched prior dlck-Cre characterization, confirming that the discordance reflects loss of EYFP detection rather than ectopic tdTomato expression. The author concludes that this EYFP reporter (and likely similar EYFP-based Rosa26 constructs) fails to label a sizeable subset of Cre⁺ cells, with major implications for lineage tracing, use of EYFP⁻ cells as “internal Cre⁻ controls,” and interpretation of inducible or asynchronous Cre systems.

These results echo the persistent challenges inherent to macrophage- and monocyte-specific Cre lines: none offers both full penetrance and absolute specificity. Instead, drivers such as LysM-Cre, Cx3cr1-Cre/CreER, Csf1r-Mer-iCre-Mer, and CD11b-Cre display overlapping myeloid labeling, tissue- and ontogeny-dependent variability, and recombination efficiencies that fluctuate with locus and induction (Ren, Williams groups and write-up by Jakubzick & Janssen group). We talk about this a little bit in my recent review in elife as well (Damani-Yokota & Khanna). In this context, the binary “split-Cre” strategy pioneered by Steffen Jung’s group, in which N- and C-terminal Cre fragments are driven by distinct promoters (e.g., Sall1^nCre × Cx3cr1^cCre or Lyve1^nCre × Cx3cr1^cCre), has emerged as an elegant way to intersectionally target microglia and CNS border-associated macrophages with exceptional specificity, albeit at the predictable cost of somewhat reduced overall recombination efficiency compared with conventional single-promoter Cre lines (Jung).

Florent Ginhoux’s monocyte/macrophage fate-mapping Ms4a3Cre and Ms4a3CreERT2 lines, originally described (in Cell) , label granulocyte–monocyte progenitors and their monocyte/granulocyte progeny with high efficiency while sparing lymphocytes and most tissue DCs, enabling precise quantification of monocyte contributions to resident macrophage pools across tissues and inflammation models. These Ms4a3-based models have since been deployed to dissect monocyte fates in pancreatic cancer, cochlear macrophage ontogeny , and brain-infiltrating macrophages after injury, often in combination with scRNA-seq and multi-omics (Ginhoux, Okano, Ginhoux & Okano, and Rossi groups). Parallelly, CCR2-CreER mice as a tamoxifen-inducible monocyte-tracing line, widely used to track Ly6C^hi/lo monocytes and their progeny in brain microglia, border-associated macrophages, and other tissues (Kuan group). Despite being powerful systems, they come with known blind spots: Ms4a3 labels GMP-derived monocytes but not embryonic progenitors, CCR2 misses CCR2⁻ monocyte compartments and can label some non-macrophage myeloid cells, and both depend on reporter alleles whose recombination efficiency and expression thresholds vary (Williams, Smith and Ren groups).

In our research as macrophage biologists that are ardently establishing systems for specific depletion of nerve associated CD169+ macrophages (Khanna group and NAMs), the cre-lox system and the inherent flaws are critical. A pragmatic path forward, in light of this EYFP–tdTomato discordance and the imperfections of macrophage Cre systems, is to treat any single Cre–reporter combination as a hypothesis generator rather than ground truth. I am still learning the system and there are others that are far more advanced in their use and understanding of these systems. With all this in mind, some things that I (and many others) have been thinking about are conceptual and technical steps that need to be taken henceforth:

(i) favoring brighter, high-dynamic-range reporters like tdTomato (or dual fluorophores) and validating them head-to-head when possible;

(ii) combining complementary drivers (e.g., Ms4a3Cre/CreERT2 plus CCR2-CreER, or Csf1r-Mer-iCre-Mer) to bracket the monocyte- versus embryonic-derived macrophage space;

(iii) using intersectional strategies (e.g., Cre/Dre or Cre/Flp systems such as CD45-Dre × Gata6-CreER for cavity macrophages) to restrict labeling to defined ontogeny–tissue niches; and

(iv) quantifying recombination directly at both the reporter and the floxed allele by flow, PCR, or single-cell multi-omics in each tissue and time point of interest.

Maybe If we standardize these validation steps and report them transparently, we can still obtain robust, reproducible, and biologically meaningful insights from monocyte/macrophage Cre systems even while fully acknowledging that every current tool is, by design, an imperfect lens on myeloid biology.


Generated using ChatGPT - a graphical abstract of points discussed in this article.


Day 2

Understanding the complex differentiation program of Hematopoietic Stem Cells towards a macrophage lineage

I’ve been reading a lot about how hematopoietic stem cells in the (mouse) bone marrow result in delineation of diverse myeloid fates such as a monocyte, macrophage, eosinophil, neutrophil or a dendritic cell. Considering the dynamic shifts in the BM due to peripheral triggers in mucosal and lymphoid tissues caused by pathology from aging, metabolic changes, infections, disease, damage and allergy - it is critical to thoroughly investigate the two-way traffic of the BM.

As HSCs in the mouse BM commit to the monocyte–macrophage lineage, they progressively trade a stem-like SLAM signature for a palette of myeloid and macrophage-defining markers. Classic immunology texts still depict this as a stepwise path from LT-HSC → ST-HSC/MPP → CMP → GMP → monocyte-lineage progenitors → monocytes → macrophages, which has now been refined by single-cell and fate-mapping studies. In flow cytometry, LT-HSCs are gated as Lin⁻ Sca-1⁺ c-Kit⁺ (LSK) CD150⁺ CD48⁻ CD34⁻, while myeloid-biased MPP2/3 remain LSK but become CD48⁺ with altered CD150/Flt3 expression. As cells drop Sca-1 and enter the Lin⁻ Sca-1⁻ c-Kit⁺ (LK) compartment, common myeloid progenitors (CMPs) appear as CD34⁺ CD16/32^lo, and granulocyte–monocyte progenitors (GMPs) as CD34⁺ CD16/32^hi, marking the first strong commitment to granulocyte/monocyte output. From here, monocyte-biased branches give rise to monocyte–dendritic progenitors (MDPs; Lin⁻ Sca-1⁻ c-Kit⁺ CD115⁺ Flt3⁺ CX3CR1⁺) and then common monocyte progenitors (cMoPs; Lin⁻ c-Kit⁺ CD115⁺ CX3CR1⁺ Ly6C⁺ Flt3⁻), a hierarchy consolidated in recent myeloid heterogeneity reviews. At this point, intracellular transcription factors such as IRF8, PU.1 (SPI1), and KLF4 are up-regulated, steering cells away from neutrophil and DC fates toward a monocyte–macrophage identity.

Within the bone marrow niche, cMoPs mature into Ly6C^hi CXCR4^hi pre-monocytes (preMos) and then Ly6C^hi CXCR4^lo monocytes, which are poised for egress to blood. These transitional preMos remain Lin⁻ CD115⁺ Ly6C^hi CXCR4^hi CCR2⁺ and still proliferate, whereas more mature Ly6C^hi monocytes acquire CD11b⁺ CX3CR1^lo and become strongly CCR2-dependent for exit—features nicely summarized in recent ontogeny reviews. As monocytes settle into tissue macrophage niches (or remain as marrow macrophages), they upregulate canonical macrophage markers such as F4/80 (Adgre1), CD64 (FcγRI), MerTK, and high CD11b, while maintaining CD115; at the transcriptional level, MafB, c-Maf, and sustained PU.1 consolidate macrophage identity.

Together, these surface and intracellular markers give you a practical flow-cytometry toolkit to track the moment when a generic myeloid progenitor “decides” to become a monocyte/macrophage in the mouse bone marrow.

I generated the image (below) using ChatGPT to make this more clear.. please tell me if things are either incorrect or outdated and I will refine this better.

Image generated using ChatGPT with a lot of errors that I am working on fixing

#DecemberAdventure

References:

https://www.labome.com/method/Macrophage-Markers.html?utm_source=chatgpt.com

https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B9780120749034500327?utm_source=chatgpt.com

https://www.studocu.com/en-us/document/university-of-mississippi/immunology-and-serology/kuby-immunology-8th-ed-ch-2-lecture-slides-immune-system-cells-organs/138995937?utm_source=chatgpt.com

https://rupress.org/jem/article/213/11/2293/42007/CXCR4-identifies-transitional-bone-marrow

https://pmc.ncbi.nlm.nih.gov/articles/PMC10917229/?utm_source=chatgpt.com

https://www.nature.com/articles/s41586-024-07186-6?utm_source=chatgpt.com

https://www.mdpi.com/1422-0067/24/10/8757?utm_source=chatgpt.com

https://pmc.ncbi.nlm.nih.gov/articles/PMC9256773/?utm_source=chatgpt.com

https://pmc.ncbi.nlm.nih.gov/articles/PMC5726802/?utm_source=chatgpt.com

https://www.nature.com/articles/s41586-024-07186-6?utm_source=chatgpt.com

https://cuvas.edu.pk/cuvas_libraries/ebooks/Owen%20Kuby%20Immunology%207th%20%20Ed.%20%282013%29.pdf?utm_source=chatgpt.com

December Adventure & Day 1

Take a journey with me as I start a #DecemberAdventure starting tomorrow for 25 days. This has been on my list of things to do for many years, especially as I read these posts on Mastodon/BSKY each year by programmers who pick a project and chip at it each day for the advent calendar.

How this is going to work is simple: I will try to write a blog post each day for 25 days of December starting tomorrow that talks about something I am doing/learning from a published paper, textbook chapter, a seminar.. heck even my group meeting at work. It can also be something I am trying to do for a manuscript/project. It’ll be pretty broad just so I can muster up the motivation to follow through.

So, come on this adventure with me!

(Day 0, #DecemberAdventure)

Day 1

Rewriting Immunity: Epigenetic Memory and the Rise of Trained Type-2 Responses

I have been fascinated with type 2 immunity for a good part of a decade and decided to re-read this fabulous review by Franziska Hartung and Julia Esser-von Bieren, Trained immunity in type 2 immune responses. Hartung and Bieren beautifully synthesize emerging evidence that trained immunity plays a substantial role in shaping type 2 immune responses such as helminth infection, allergy, and asthma. Definition of trained immunity according to leading experts in the field, is “long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and which leads to an altered response towards a second challenge after the return to a non-activated state.” This type of epigenetic and metabolic programming can act on long lived innate cells such as NK cells, macrophages and monocytes, HSCs. More recently, there's been suggestions of innate memory potential on eosinophils and ILCs as well.

In thinking about this review and rather than regurgitating the highlights..I’d like to just think out loud- some of the broad strokes about type 2 immunity.

One thing that has always struck out to me is how anything that doesn’t fit in type 1 immunity is bucketed as a type 2 immunity. But, the reality is that type 2 immunity has a wide spectrum from allergy, autoimmunity, asthma, helminths infections, metabolic diseases as well as fibrosis. Having said that, you can imagine how complex the triggers and the resulting consequences can be.

For instance, a helminth infection and an asthmatic response may result in eosinophilia, yet the consequences of this exuberant eosinophilia can be incredibly host protective during helminths infection in mounting a robust type 2 immune response against a secondary helminth infection.. while maintenance of such eosinophils can also be immensely pathogenic and inflammatory in asthma. This complexity is telling of how underappreciated the diverse type 2 immune responses really are.

This is almost a conversation starter and we can let this incubate and circle back to it and let it evolve over this month. But, as far as the review goes.. one of the many enigmatic and open questions that still remain in the field of trained immunity and type 2 immunity - I hadn’t thought much about this one:

Do IL-33-responsive progenitors in the bone marrow form a long-term memory niche that sustains chronic asthma even in the absence of allergen exposure. If so, can this explain why there is a persistent inflammation in CRSwNP and NSAID-exacerbated diseases. Why don’t you chew on that for a bit and I’ll think of something else to talk about tomorrow.

#DecemberAdventure